Viral haemorrhagic fever (VHF) refers to a group of severe and potentially life-threatening illnesses caused by several types of viruses. It is characterized by fever, widespread vascular damage, and bleeding both internally and externally. The condition typically progresses rapidly and can result in significant morbidity and mortality.
Viral haemorrhagic fever is caused by a variety of viruses including Ebola, Marburg, Lassa, and Crimean-Congo fever virus, to name a few. These viruses are primarily transmitted to humans through contact with infected animals, such as rodents or primates, or through direct contact with bodily fluids of infected individuals.
Symptoms of viral haemorrhagic fever can vary depending on the specific virus, but commonly include sudden fever, fatigue, muscle aches, dizziness, and headaches. As the disease progresses, patients may experience more severe symptoms, including vomiting, diarrhoea, internal and external bleeding, organ failure, and even death.
Management of viral haemorrhagic fever consists mainly of supportive care, including hydration, maintaining electrolyte balance, and treatment of complicating symptoms. In some cases, antiviral medications may be used if available and effective against the specific virus causing the illness.
Given the potential for rapid spread and high mortality rates associated with viral haemorrhagic fever, strict infection control measures need to be implemented to prevent further transmission. This typically includes isolation of infected individuals, protective barrier methods, and appropriate decontamination procedures.